NDAORALTABLET
Approved
Oct 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 48m ago · AI intelligence enriched 6h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOSAT is a potassium iodide oral tablet approved in 1982 for emergency thyroid protection in radiation exposure scenarios. It works by saturating the thyroid gland with stable iodide, blocking uptake of radioactive iodine. This is a critical public health countermeasure rather than a chronic therapeutic agent.
LOE Approaching
As lifecycle approaches end-of-exclusivity with moderate competitive pressure (30), the brand team is likely small and focused on regulatory compliance and emergency preparedness rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles linked to IOSAT are heavily weighted toward manufacturing operations, maintenance, and validation rather than commercial or medical functions, reflecting the product's stable, high-volume supply-chain focus. Career trajectory on this product emphasizes technical excellence in GMP manufacturing and emergency-preparedness logistics over traditional pharma commercial advancement.
ELECTRICIAN
Worked on IOSAT at Mission Pharmacal? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.